Inhibition of replication of primary HIV-1 isolates in huPBL-NOD/Scid mice by antibodies from HIV-1 infected patients

Andrus, 1998, Passive immunization with a human immunodeficiency virus type 1-neutralizing monoclonal antibody in hu-PBL-SCID mice: isolation of a neutralization escape variant, J. Infect. Dis., 177, 889, 10.1086/515251 Barbas, 1993, Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries, J. Mol. Biol., 230, 812, 10.1006/jmbi.1993.1203 Beddows, 2005, Neutralization sensitivity of HIV-1 Env-pseudotyped virus clones is determined by co-operativity between mutations which modulate the CD4-binding site and those that affect gp120-gp41 stability, Virology, 337, 136, 10.1016/j.virol.2005.03.033 Beirnaert, 2000, Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates, J. Med. Virol., 62, 14, 10.1002/1096-9071(200009)62:1<14::AID-JMV3>3.0.CO;2-L Beirnaert, 1998, Design and evaluation of an in-house HIV-1 (group M and O), SIVmnd and SIVcpz antigen capture assay, J. Virol. Meth., 73, 65, 10.1016/S0166-0934(98)00044-5 Binley, 1997, Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1, J. Virol., 71, 2799, 10.1128/JVI.71.4.2799-2809.1997 Binley, 2004, Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies, J. Virol., 78, 13232, 10.1128/JVI.78.23.13232-13252.2004 Boyle, 1995, The human HIV/peripheral blood lymphocyte (PBL)-SCID mouse. A modified human PBL-SCID model for the study of HIV pathogenesis and therapy, J. Immunol., 154, 6612 Buchacher, 1994, Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization, AIDS Res. Hum. Retrovir., 10, 359, 10.1089/aid.1994.10.359 Burton, 1991, A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals, Proc. Natl. Acad. Sci. U.S.A., 88, 10134, 10.1073/pnas.88.22.10134 Burton, 1994, Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody, Science, 266, 1024, 10.1126/science.7973652 Calarese, 2003, Antibody domain exchange is an immunological solution to carbohydrate cluster recognition, Science, 300, 2065, 10.1126/science.1083182 Cao, 1995, Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection, N. Engl. J. Med., 332, 201, 10.1056/NEJM199501263320401 Cecilia, 1999, A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects, J. Infect. Dis., 179, 1365, 10.1086/314773 Cherpelis, 2001, DNA vaccination with the human immunodeficiency virus type 1 SF162ΔV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8+ T-cell-depleted rhesus macaques, J. Virol., 75, 1547, 10.1128/JVI.75.3.1547-1550.2001 Conley, 1994, Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody, Proc. Natl. Acad. Sci. U.S.A., 91, 3348, 10.1073/pnas.91.8.3348 Donners, 2003, The first generation of candidate HIV-1 vaccines can induce antibodies able to neutralize primary isolates in assays with extended incubation phases, Vaccine, 22, 104, 10.1016/S0264-410X(03)00530-9 Donners, 2002, Cross-neutralizing antibodies against primary isolates in African women infected with HIV-1, AIDS, 16, 501, 10.1097/00002030-200202150-00030 D'Souza, 1997, Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. AIDS Clinical Trials Group Antibody Selection Working Group, J. Infect. Dis., 175, 1056, 10.1086/516443 Gauduin, 1997, Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1, Nat. Med., 3, 1389, 10.1038/nm1297-1389 Haynes, 2005, Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies, Science, 308, 1906, 10.1126/science.1111781 Ho, 2005, A shot in the arm for AIDS vaccine research, PLoS Med., 2, e36, 10.1371/journal.pmed.0020036 Klausner, 2003, Medicine. The need for a global HIV vaccine enterprise, Science, 300, 2036, 10.1126/science.1086916 Louwagie, 1993, Phylogenetic analysis of gag genes from 70 international HIV-1 isolates provides evidence for multiple genotypes, AIDS, 7, 769, 10.1097/00002030-199306000-00003 Mascola, 1999, Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies, J. Virol., 73, 4009, 10.1128/JVI.73.5.4009-4018.1999 Moore, 2004, Urgently needed: a filter for the HIV-1 vaccine pipeline, Nat. Med., 10, 769, 10.1038/nm0804-769 Muster, 1993, A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1, J. Virol., 67, 6642, 10.1128/JVI.67.11.6642-6647.1993 Nkengasong, 1994, Genotypic subtypes of HIV-1 in Cameroon, AIDS, 8, 1405, 10.1097/00002030-199410000-00006 Osmanov, 2002, Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000, J. Acquir. Immune Defic. Syndr., 29, 184, 10.1097/00042560-200202010-00013 Parren, 2001, Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro, J. Virol., 75, 8340, 10.1128/JVI.75.17.8340-8347.2001 Pilgrim, 1997, Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection, J. Infect. Dis., 176, 924, 10.1086/516508 Poignard, 1999, Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo, Immunity, 10, 431, 10.1016/S1074-7613(00)80043-6 Roben, 1994, Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1, J. Virol., 68, 4821, 10.1128/JVI.68.8.4821-4828.1994 Sanders, 2002, The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120, J. Virol., 76, 7293, 10.1128/JVI.76.14.7293-7305.2002 Saphire, 2001, Crystal structure of a neutralizing human IgG against HIV-1: a template for vaccine design, Science, 293, 1155, 10.1126/science.1061692 Scanlan, 2002, The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of α1→2 mannose residues on the outer face of gp120, J. Virol., 76, 7306, 10.1128/JVI.76.14.7306-7321.2002 Schutten, 1996, Human antibodies that neutralize primary human immunodeficiency virus type 1 in vitro do not provide protection in an in vivo model, J. Gen. Virol., 77, 1667, 10.1099/0022-1317-77-8-1667 Shultz, 1995, Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice, J. Immunol., 154, 180 Stiegler, 2001, A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1, AIDS Res. Hum. Retrovir., 17, 1757, 10.1089/08892220152741450 Tanaka, 1993, Selective long-term elimination of natural killer cells in vivo by an anti-interleukin 2 receptor β chain monoclonal antibody in mice, J. Exp. Med., 178, 1103, 10.1084/jem.178.3.1103 Tournoy, 2000, Mouse strain and conditioning regimen determine survival and function of human leucocytes in immunodeficient mice, Clin. Exp. Immunol., 119, 231, 10.1046/j.1365-2249.2000.01099.x Trkola, 2005, Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies, Nat. Med., 11, 615, 10.1038/nm1244 Trkola, 1995, Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG, J. Virol., 69, 6609, 10.1128/JVI.69.11.6609-6617.1995 Trkola, 1996, Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1, J. Virol., 70, 1100, 10.1128/JVI.70.2.1100-1108.1996 Veazey, 2003, Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120, Nat. Med., 9, 343, 10.1038/nm833 Zwick, 2001, Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41, J. Virol., 75, 10892, 10.1128/JVI.75.22.10892-10905.2001